» Articles » PMID: 9737584

Effect of Major Deletions in the V1 and V2 Loops of a Macrophage-tropic HIV Type 1 Isolate on Viral Envelope Structure, Cell Entry, and Replication

Overview
Publisher Mary Ann Liebert
Date 1998 Sep 16
PMID 9737584
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Two HIV-1 envelope mutant proteins were generated by introducing deletions in the first and second hypervariable gp120 regions (V1 and V2 loops, respectively) of a macrophage-tropic primary HIV-1 isolate, SF162, to study the effect of the deleted sequences on envelope structure, viral entry, and replication potentials. The first mutant lacked 17 amino acids of the V1 loop and the latter 30 amino acids of the V2 loop. A comparison of the immunochemical structure of the wild-type and mutant monomeric and virion-associated gp120 molecules revealed that the V1 and V2 loop deletions differentially altered the structure of the V3 loop, the CD4-binding site, and epitopes within conserved regions of gp120. Regardless of differences in structure, both mutated envelope proteins supported viral replication into peripheral blood mononuclear cells to levels comparable to those of the wild-type SF162 virus. However, they decreased the viral replication potential in macrophages, even though they did not alter the coreceptor usage of the viruses. These studies support and extend previous observations that a complex structural interaction between the V1, V2, and V3 loops and elements of the CD4-binding site of gp120 controls entry of virus into cells. The present studies, however, suggest that the effect of the V1 and V2 loops in viral entry is cell dependent.

Citing Articles

Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.

Rao P, Lambert G, Upadhyay C J Virol. 2023; 97(9):e0071023.

PMID: 37681958 PMC: 10537810. DOI: 10.1128/jvi.00710-23.


Serinc5 Restricts HIV Membrane Fusion by Altering Lipid Order and Heterogeneity in the Viral Membrane.

Ward A, Sokovikova D, Waxham M, Heberle F, Levental I, Levental K ACS Infect Dis. 2023; 9(4):773-784.

PMID: 36946615 PMC: 10366416. DOI: 10.1021/acsinfecdis.2c00478.


Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.

Schapiro H, Khasnis M, Ahn K, Karagiaridi A, Hayden S, Cilento M PLoS Pathog. 2022; 18(5):e1010531.

PMID: 35584191 PMC: 9154124. DOI: 10.1371/journal.ppat.1010531.


A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.

Rubio A, Filsinger Interrante M, Bell B, Brown C, Bruun T, LaBranche C J Virol. 2021; 95(15):e0235020.

PMID: 33980592 PMC: 8274607. DOI: 10.1128/JVI.02350-20.


A reversed phase HPLC method for the quantification of HIV gp145 glycoprotein levels from cell culture supernatants.

Gonzalez-Feliciano J, Capo-Velez C, Akamine P, Delgado-Velez M, Almodovar R, Rivera J J Chromatogr B Analyt Technol Biomed Life Sci. 2021; 1167:122562.

PMID: 33571843 PMC: 8041096. DOI: 10.1016/j.jchromb.2021.122562.